| AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic Castration-Resistant Prostate Cancer (mCRPC). | |
|
| A globe-spanning scientific team has compiled the most comprehensive list of genetic variants associated with prostate cancer risk -; 451 in all -; through a whole-genome analysis that ranks as the largest and most diverse investigation into prostate cancer genetics yet. | |
|
| The associations between body mass index (BMI) among young males and new-onset site-specific tumors. | |
|
| Cedars-Sinai Cancer investigators have found that Black men respond as well as white men to systemic therapies for advanced prostate cancer when access to quality healthcare is equal, regardless of socioeconomic status. | |
|
| Men who are overweight or obese at age 18 have a higher risk of 17 different cancers later in life. This has been shown in a study at the University of Gothenburg. | |
|
| Epigenetic changes can cause prostate cancer to resist treatment by switching genes on or off. One epigenetic mechanism tags genes with DNA methylation marks. | |
|
| Scientists at deCODE genetics, a subsidiary of Amgen, have published a study on actionable genotypes detected in the Icelandic population and their association with lifespan. | |
|
| Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis. | |
|
| Black men in the United States are more likely to develop prostate cancer than white men, and after diagnosis, they're more likely to have advanced disease and to die than white men with the disease. | |
|
| New research finds little evidence that post-surgical patient mortality is lower when patient and surgeon are the same gender. | |